Moreover, in accordance with several publications, we could ascertain a higher prevalence of HER2-low tumors among hormone receptor positive/HER2-negative breast tumors in comparison to tumors with a triple negative phenotype (Miglietta et al. 2021; Rossi et al. 2012; Sapino et al. 2014; Schettini et al. 2021). Here, ERBB2 is linked to breast neoplasm.